The exopolysaccharide (EPS) was produced by a halophilic bacterial strain isolated from marine sediments, Porto-Elsokhna Beach, Egypt. This isolate has been defined morphologically and physiologically and has been recognized by 16S rDNA as Bacillus axarquiensis NRC G6.This strain was deposited in the Gene Bank (http://www.ncbi.nlm.nih. gov) under the accession number of KU945823. The EPS produced was fractionated by precipitation and listed the primary fraction as EPSBa3. Through FT-IR and HPLC, further work attempted to elucidate the structural function of EPSBa3. The findings showed that EPSBa3 was an acidic EPS composed of glucuronic: mannose: galacturonic: glucose and xylose, respectively, in a molar ratio of 1:1:3:3:3.  The proportion of uronic acid and sulfate was 13.9% and 7% respectively. The estimated median molecular weight (Mw) and molecular number (Mn) were 1.499 X10⁶ and 1.29 X 10⁶g / mol. In rats, the anti-inflammatory activity of exopolysaccharide (EPSBa3) was also explored using paw edema induced by carrageenan. EPSBa3 caused important anti-inflammatory effects on the carrageenan model by 50 mg/kg orally. In catalase (CAT) and superoxide dismutase (SOD) enzymes and GSH content, the EPSBa3 enhanced declines. In addition, the content of nitric oxide (NO), lipid peroxidation (LPO) and reactive oxygen species (ROS) arising from carrageenan-induced edema were considerably reduced following therapy with EPSBa3. In addition, the findings showed that interleukin-6 (IL-6) protein expression was decreased after EPSBa3 treatment leading to alleviate paw edema. These findings stated that to avoid inflammatory diseases, EPSBa3 could be utilized as a source of natural products.